1 / 37

Learning Objectives

Learning Objectives. Metabolic Abnormalities Associated With T2D. CV Events With PPAR-gamma Agonists. Effect of Fibrates on CV Outcomes A Systematic Review and Meta-analysis. ACCORD Lipid Hazard Ratios for the Primary Outcome. Pioglitazone Meta-analysis Heart Failure & MI.

denton-mercado
Download Presentation

Learning Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Learning Objectives

  2. Metabolic Abnormalities Associated With T2D

  3. CV Events With PPAR-gamma Agonists

  4. Effect of Fibrates on CV OutcomesA Systematic Review and Meta-analysis

  5. ACCORD Lipid Hazard Ratios for the Primary Outcome

  6. Pioglitazone Meta-analysisHeart Failure & MI

  7. Dual PPAR a/g Agonists

  8. AleCardioAleglitazar (PPAR a/g Agonist) in Patients With T2D and ACS

  9. AleCardio Efficacy and Safety Outcomes

  10. AleCardioGlycemic Control and Lipoprotein Effects

  11. Genes Regulated by Glitazones

  12. Older Antidiabetic Drugs and CV Benefit/Harm

  13. SAVOR-TIMI 53Clinical End Points: Saxagliptin (DPP4 Inhibitor) vs Placebo

  14. SAVOR-TIMI 53Hospitalization for Heart Failure Stratified by NT-proBNP Quartiles

  15. SAVOR-TIMI 53Safety Endpoints

  16. EXAMINESafety End Points: Alogliptin (DPP4 Inhibitor) vs Placebo

  17. EXAMINEHeart Failure Outcomes

  18. Mechanism of Heart Failure

  19. Ongoing CVD Outcomes Trials in Type 2 Diabetes

  20. Clinical Trial Design Considerations

  21. AlePreventAleglitazar in Patients With Stable CVD and Glucose Abnormalities

  22. Newer Antidiabetic Drugs & CV Risk Reduction

  23. Concluding Remarks

  24. Abbreviations

  25. Abbreviations (cont)

  26. Abbreviations (cont)

  27. References

  28. References (cont)

  29. References (cont)

  30. References (cont)

  31. References (cont)

  32. References (cont)

  33. References (cont)

  34. References (cont)

More Related